Bratschi represented Voyager Acquisition Corp., a publicly traded Cayman Islands Special Purpose Acquisition Company (SPAC), on Swiss law related aspects concerning its announced business combination agreement with Zurich-based Veraxa Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies.
The combination will result in Veraxa Biotech AG becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a valuation of approximately USD 1.64 billion. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals.
The Bratschi team was led by Claudio Bazzi (Partner, Corporate/M&A) and included Marco Rizzi (Partner, Corporate/M&A), Michael Barrot (Partner, Tax), Adrian Bieri (Partner, IP), Felix Kesselring (Partner, Life Sciences), Daniel Mosimann (Associate, Corporate/M&A), Stephanie Caprani-Pontes (Associate, Corporate/M&A) and Rico Dufner (Associate, Tax).
Bratschi advised the management of SSP KÄLTEPLANER AG on the structuring and execution of the management buy-out.
Bratschi AG has once again received extensive recognition in the latest edition of the «The Legal 500 EMEA 2026» rankings. Its strong position in the Construction practice area is particularly noteworthy, with Bratschi successfully defending its Tier 1 ranking.
Bratschi AG recognised in the Chambers Europe Guide 2026 – first-time ranking in two new practice areas